Membrane-Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans-Golgi Network

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• The NLRP3 inflammasome is central to innate immunity and implicated in age-related inflammatory diseases.
• Dysregulated NLRP3 activation presents a therapeutic target for inflammatory conditions.

Purpose of the Study:

• To investigate the direct inhibitory effects of the synthetic peptide Pep19-2.5 on NLRP3 inflammasome activation.
• To elucidate the mechanism of action and therapeutic potential of Pep19-2.5 in inflammatory disease models.

Main Methods:

• Cellular, biophysical, and biochemical analyses were employed to study Pep19-2.5's effects on NLRP3 inflammasome signaling.
• Interaction of Pep19-2.5 with macrophage membranes and lipid structures was investigated.
• In vitro studies used human macrophages stimulated with house dust mite (HDM) extract.
• An in vivo HDM-induced allergic airway inflammation mouse model was used to assess therapeutic efficacy.

Main Results:

• Pep19-2.5 directly inhibits NLRP3 inflammasome activation downstream of NLRP3 assembly.
• The peptide interacts with macrophage membranes and phosphatidylinositol (PI)-containing lipid membranes, potentially affecting NLRP3 recruitment.
• Pep19-2.5 suppressed IL-1β secretion induced by HDM extract in human macrophages.
• Nasal aerosol administration of Pep19-2.5 reduced IL-1β levels, eosinophil infiltration, and improved lung function in a mouse model of allergic airway inflammation.

Conclusions:

• Pep19-2.5 acts as a direct inhibitor of the NLRP3 inflammasome through membrane interaction.
• The peptide demonstrates significant therapeutic potential for treating NLRP3-driven inflammatory diseases, including allergic airway inflammation.
• Pep19-2.5 offers a promising therapeutic strategy targeting the NLRP3 inflammasome pathway.